EKF in kidney biomarker licence agreement

EKF Diagnostics Holdings, a manufacturer of point of care in-vitro diagnostic devices, has signed an exclusive agreement with the Joslin Diabetes Center, an affiliate of Harvard Medical School, to license certain novel kidney disease recognition technology.

EKF Diagnostics Holdings, a manufacturer of point of care in-vitro diagnostic devices, has signed an exclusive agreement with the Joslin Diabetes Center, an affiliate of Harvard Medical School, to license certain novel kidney disease recognition technology.

The licence will provide EKF's wholly owned subsidiary, Argutus Medical, with exclusive rights to the Joslin's intellectual property surrounding two biomarkers, Tumor Necrosis Factor Receptor 1 and 2, that, when found elevated in the blood stream, can help identify patients with Type 1 and Type 2 diabetes at increased risk of developing end stage renal disease up to ten years in advance.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
MoneyWeek

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.